Novigenix is a precision medicine Tech Bio offering state-of-the-art ImmunoTranscriptomic liquid biopsy solutions with unprecedented predictive capabilities for precision development of novel therapeutics.
Our AI-enabled ISO-13485 certified RNA analytic platform delivers ImmunoPD biomarkers, insights into mechanism of action and resistance, and early markers for severe toxicity to accelerate clinical development. These scalable solutions are currently adopted in a number of FDA clinical trials providing actionable insights across therapeutic modalities including ADCs, radioligand therapy, cellular therapies, therapeutic vaccines, and immunotherapies.
The LITOSeek™ Liquid ImmunoTranscriptOmic platform has been optimized for mapping the response of patient immune system to onset of disease and therapeutic intervention. Proprietary analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches for early detection of disease, development of novel therapeutics, and drug target discovery.
Company Details
- Employees
- 25
- Founded
- -
- Address
- Route De La Corniche 3, Lausanne,vd 1066,switzerland
- va****@****nix.com
- Industry
- Biotechnology
- Website
- novigenix.com
- Keywords
- Liquid Biopsy, Precision Oncology, Drug Development, Early Cancer Detection, Drug Target Discovery, ML & AI.
- HQ
- Lausanne, VD
Novigenix Sa Questions
Novigenix Sa's website is novigenix.com
Novigenix Sa's LinkedIn profile is https://ch.linkedin.com/company/novigenix
Novigenix Sa has
25 employees.
View email and phone details for 25
employees at Novigenix Sa.
Novigenix Sa's industry is
Biotechnology
Novigenix Sa's top competitors are
Tethis S.p.a,
Alithea Genomics,
Hedera Dx,
Adaptyv,
Biopôle Lausanne,
Newbiologix,
Lunaphore (A Bio-Techne Brand),
Cellestia Biotech,
Limula,
Haya Therapeutics.
Novigenix Sa's support email address is valentin.matillon@novigenix.com
Novigenix Sa's categories are Biotechnology
Novigenix Sa's founding year is 2014
